Citigroup Inc. Increases Position in Hologic, Inc. (NASDAQ:HOLX)

Citigroup Inc. boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 3.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,042,574 shares of the medical equipment provider's stock after buying an additional 38,362 shares during the period. Citigroup Inc. owned 0.45% of Hologic worth $84,928,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Wolff Wiese Magana LLC acquired a new stake in shares of Hologic during the 3rd quarter worth about $25,000. Innealta Capital LLC purchased a new stake in shares of Hologic in the 2nd quarter valued at approximately $25,000. iA Global Asset Management Inc. acquired a new position in shares of Hologic in the 1st quarter worth approximately $37,000. First Horizon Advisors Inc. boosted its position in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after purchasing an additional 134 shares during the period. Finally, Sunbelt Securities Inc. purchased a new stake in Hologic in the second quarter valued at approximately $37,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Up 0.3 %

Hologic stock traded up $0.25 during mid-day trading on Friday, hitting $78.97. The company had a trading volume of 1,258,491 shares, compared to its average volume of 1,682,785. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 1 year low of $67.59 and a 1 year high of $84.67. The business has a fifty day moving average of $80.44 and a 200 day moving average of $78.32. The stock has a market cap of $18.34 billion, a price-to-earnings ratio of 23.71, a PEG ratio of 2.48 and a beta of 0.98.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts' consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million during the quarter, compared to analysts' expectations of $978.25 million. During the same period in the previous year, the company earned $0.89 earnings per share. Hologic's quarterly revenue was up 4.5% compared to the same quarter last year. On average, sell-side analysts expect that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Evercore ISI raised their price target on Hologic from $78.00 to $82.00 and gave the stock an "in-line" rating in a research report on Tuesday, October 1st. Royal Bank of Canada boosted their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a "sector perform" rating in a research note on Tuesday, November 5th. Stephens restated an "overweight" rating and issued a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th. StockNews.com upgraded shares of Hologic from a "hold" rating to a "buy" rating in a report on Thursday, November 14th. Finally, Raymond James boosted their price target on shares of Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Hologic currently has an average rating of "Moderate Buy" and a consensus price target of $89.91.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.